Related Experiment Videos
Novel isoforms of human cyclic AMP-responsive element modulator (hCREM) mRNA
T Fujimoto1, J Fujisawa, M Yoshida
1Department of Cellular and Molecular Biology, University of Tokyo.
Journal of Biochemistry
|February 1, 1994
Summary
Researchers identified two human CREM (CRE-modulator) cDNA types. Type 2 is a novel form that, along with type 1, suppresses cyclic AMP-mediated transcription, indicating a negative regulatory role.
Area of Science:
- Molecular Biology
- Gene Regulation
- Transcriptional Control
Background:
- The cyclic AMP-response element (CRE) is a transcriptional enhancer regulated by CREB (CRE-binding protein).
- CREM (CRE-modulator), a homolog of CREB, modulates CREB-stimulated transcription and is involved in spermatogenesis.
- Understanding CREM isoforms is crucial for deciphering gene regulation pathways.
Purpose of the Study:
- To identify and characterize different types of human CREM (hCREM) cDNAs.
- To investigate the functional differences and expression patterns of hCREM isoforms.
- To elucidate the role of hCREM in regulating cAMP-mediated transcription.
Main Methods:
- cDNA cloning and sequencing to identify hCREM types.
- Analysis of unique 5' exon regions for distinct regulatory elements.
- Expression studies in lymphoid and non-lymphoid cell lines.
- Transfection experiments to assess the impact of excess hCREM expression on transcription.
Main Results:
- Two types of hCREM cDNAs were identified: type 1 (human counterpart of mouse CREM alpha) and type 2 (a novel form).
- Type 2 hCREM possesses a unique 5' exon, suggesting independent expression and distinct functional roles.
- Both hCREM types are expressed in various cell lines and suppress cAMP-mediated transcriptional activation when overexpressed.
Conclusions:
- Human CREM exists in at least two distinct cDNA forms, type 1 and type 2.
- Type 2 hCREM represents a novel isoform with a unique regulatory region.
- Both hCREM types act as negative regulators of CRE-mediated transcription, impacting cAMP signaling pathways.